{"id":"ace-536","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Bone pain"},{"rate":null,"effect":"Thrombotic events"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ACE-536 binds to activin type II receptors, blocking activin signaling which normally suppresses red blood cell production. By inhibiting this negative regulator of erythropoiesis, the drug stimulates the bone marrow to produce more red blood cells, thereby increasing hemoglobin and reducing anemia. This mechanism is distinct from traditional erythropoiesis-stimulating agents (ESAs) as it works through a different pathway.","oneSentence":"ACE-536 is an activin receptor ligand trap that inhibits activin signaling to promote erythropoiesis and increase hemoglobin levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:05.125Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Beta-thalassemia"},{"name":"Myelodysplastic syndromes (MDS)"}]},"trialDetails":[{"nctId":"NCT07463820","phase":"PHASE2","title":"A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-19","conditions":"Myelodysplastic Syndrome","enrollment":270},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT06788691","phase":"PHASE2","title":"Luspatercept for Clonal Cytopenias of Uncertain Significance","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2025-03-25","conditions":"CCUS Clonal Cytopenia of Undetermined Significance, Anemia, Leukopenia","enrollment":50},{"nctId":"NCT05664737","phase":"PHASE2","title":"A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2022-12-09","conditions":"Anemia","enrollment":189},{"nctId":"NCT05949684","phase":"PHASE3","title":"ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-10-24","conditions":"Myelodysplastic Syndromes","enrollment":360},{"nctId":"NCT07096297","phase":"PHASE2","title":"Luspatercept + Darbepoetin in MDS","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-12-16","conditions":"MDS (Myelodysplastic Syndrome)","enrollment":60},{"nctId":"NCT07465029","phase":"","title":"A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-02-02","conditions":"Lower-risk Myelodysplastic Syndromes (TD LR-MDS)","enrollment":1300},{"nctId":"NCT05181735","phase":"PHASE1, PHASE2","title":"Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA","status":"RECRUITING","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2022-05-18","conditions":"MDS, Myelodysplastic Syndromes","enrollment":150},{"nctId":"NCT07450313","phase":"PHASE2","title":"The Efficacy and Safety of Luspatercept in Improving Early Anemia After HSCT","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-14","conditions":"HSCT","enrollment":20},{"nctId":"NCT07215975","phase":"","title":"A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-02-26","conditions":"β-thalassemia","enrollment":200},{"nctId":"NCT06851065","phase":"","title":"A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United States","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2024-08-22","conditions":"Myelodysplastic Syndromes","enrollment":418},{"nctId":"NCT04419649","phase":"PHASE2","title":"A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)","status":"RECRUITING","sponsor":"Takeda","startDate":"2020-08-19","conditions":"Myelodysplastic Syndromes, Cytopenia","enrollment":160},{"nctId":"NCT07362095","phase":"PHASE1, PHASE2","title":"Luspatercept for the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT)","status":"RECRUITING","sponsor":"Zhujiang Hospital","startDate":"2025-10-01","conditions":"Acute Leukemia","enrollment":46},{"nctId":"NCT07338344","phase":"PHASE2","title":"Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients","status":"RECRUITING","sponsor":"Rongrong Liu","startDate":"2026-02-01","conditions":"Transfusion-dependent β-thalassemia Patients","enrollment":78},{"nctId":"NCT07331818","phase":"PHASE2","title":"Luspatercept in Patients Affected With Rare Inherited Anemias","status":"NOT_YET_RECRUITING","sponsor":"EuroBloodNet Association","startDate":"2026-01-15","conditions":"Hereditary Red Blood Cell Disorder (Disorder)","enrollment":45},{"nctId":"NCT04143724","phase":"PHASE2","title":"Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia","status":"RECRUITING","sponsor":"Celgene","startDate":"2019-11-07","conditions":"Beta-Thalassemia","enrollment":99},{"nctId":"NCT06517875","phase":"PHASE2","title":"Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-02-28","conditions":"Primary Myelofibrosis, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis","enrollment":56},{"nctId":"NCT05732961","phase":"PHASE2","title":"Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-02-21","conditions":"Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Anemia","enrollment":70},{"nctId":"NCT04064060","phase":"PHASE3","title":"A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials","status":"RECRUITING","sponsor":"Celgene","startDate":"2019-08-12","conditions":"Myelodysplastic Syndromes (MDS), Beta-thalassemia, Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis","enrollment":665},{"nctId":"NCT06045689","phase":"PHASE3","title":"A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-10-05","conditions":"Myelodysplastic Syndromes","enrollment":106},{"nctId":"NCT06113302","phase":"PHASE2","title":"A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-03-01","conditions":"Myelodysplastic Syndromes","enrollment":40},{"nctId":"NCT05568225","phase":"PHASE2","title":"A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)","status":"TERMINATED","sponsor":"Forma Therapeutics, Inc.","startDate":"2022-11-15","conditions":"Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R","enrollment":17},{"nctId":"NCT05891249","phase":"PHASE4","title":"A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2023-06-05","conditions":"Anemia","enrollment":85},{"nctId":"NCT05181592","phase":"PHASE3","title":"Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome.","status":"ACTIVE_NOT_RECRUITING","sponsor":"GWT-TUD GmbH","startDate":"2021-10-27","conditions":"Myelodysplastic Syndromes","enrollment":70},{"nctId":"NCT05399732","phase":"PHASE2","title":"Efficacy and Safety in Transfusion Independent Non-severe Aplastic Anemia","status":"COMPLETED","sponsor":"Bing Han","startDate":"2022-12-19","conditions":"Aplastic Anemia","enrollment":58},{"nctId":"NCT07075406","phase":"","title":"A Study to Evaluate Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Patients With Lower-Risk Myelodysplastic Syndromes Treated With Luspatercept","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2024-11-01","conditions":"Myelodysplastic Syndromes","enrollment":250},{"nctId":"NCT05567458","phase":"PHASE2","title":"A Study to Evaluate Luspatercept (ACE-536) in Chinese Participants Who Require Regular Red Blood Cell Transfusions Due to Beta (β)-Thalassemia.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2022-10-17","conditions":"Beta-thalassemia","enrollment":94},{"nctId":"NCT04539236","phase":"PHASE1, PHASE2","title":"Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients","status":"SUSPENDED","sponsor":"Mikkael Sekeres, MD","startDate":"2021-11-09","conditions":"Myelodysplastic Syndromes","enrollment":50},{"nctId":"NCT06670222","phase":"PHASE1","title":"Oral Arsenic (ATO) in Low-risk Myelodysplastic Syndromes (MDS)","status":"RECRUITING","sponsor":"Groupe Francophone des Myelodysplasies","startDate":"2025-07-22","conditions":"Low-risk Myelodysplastic Syndromes","enrollment":24},{"nctId":"NCT07073690","phase":"","title":"Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercept in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-04-18","conditions":"Myelodysplastic Syndromes","enrollment":80},{"nctId":"NCT04717414","phase":"PHASE3","title":"An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2021-02-25","conditions":"Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis","enrollment":313},{"nctId":"NCT01688011","phase":"","title":"Connect® Myeloid Disease Registry","status":"TERMINATED","sponsor":"Celgene","startDate":"2013-12-12","conditions":"Primary Myelofibrosis, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute","enrollment":2013},{"nctId":"NCT06596642","phase":"","title":"A Real-World Study of β-Thalassemia Major Treatment With Luspatercept in Taiwan","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2024-08-21","conditions":"β-Thalassemia Major","enrollment":61},{"nctId":"NCT06971185","phase":"","title":"A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2024-11-22","conditions":"Myelodysplastic Syndromes (MDS)","enrollment":430},{"nctId":"NCT06964971","phase":"NA","title":"Treatment of Transfusion-dependent Nonsevere Aplastic Anemia With Luspatercept: a Multicenter Prospective Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Zhejiang Chinese Medical University","startDate":"2025-05-20","conditions":"Transfusion-dependent Non-severe Aplastic Anemia","enrollment":90},{"nctId":"NCT06927232","phase":"PHASE3","title":"AZA+Lus VS AZA Monotherapy in HR-MDS","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-04","conditions":"Higher-risk Myelodysplastic Syndrome","enrollment":86},{"nctId":"NCT06913634","phase":"","title":"Study to Evaluate the Long- Term Safety and Efficacy of Luspatercept in Subjects Who Received at Least One Dose of Luspatercept in the Compassionate Use Phase","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione per la Ricerca sulle Anemie ed Emoglobinopatie in Italia","startDate":"2023-05-30","conditions":"Thalassemia Major","enrollment":140},{"nctId":"NCT06875219","phase":"","title":"To Evaluate Long- Term Safety and Efficacy of Luspatercept","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione per la Ricerca sulle Anemie ed Emoglobinopatie in Italia","startDate":"2023-04-30","conditions":"Thalassemia Major","enrollment":350},{"nctId":"NCT05520749","phase":"","title":"Efficacy and Safety of Luspatercept: a Study by Fondazione Italiana Sindromi Mielodisplastiche","status":"COMPLETED","sponsor":"Fondazione Italiana Sindromi Mielodisplastiche-ETS","startDate":"2022-01-01","conditions":"Myeloid Dysplasia","enrollment":215},{"nctId":"NCT03682536","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2019-01-02","conditions":"Myelodysplastic Syndromes","enrollment":363},{"nctId":"NCT05924100","phase":"PHASE2","title":"Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD","status":"RECRUITING","sponsor":"Associazione Qol-one","startDate":"2022-11-03","conditions":"Myelodysplastic Syndromes, Del(5Q), Anemia","enrollment":22},{"nctId":"NCT06073860","phase":"","title":"A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2024-03-25","conditions":"Myelodysplastic Syndrome, Beta Thalassemia","enrollment":104},{"nctId":"NCT03900715","phase":"PHASE2","title":"An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion","status":"COMPLETED","sponsor":"Celgene","startDate":"2019-05-20","conditions":"Myelodysplastic Syndromes","enrollment":21},{"nctId":"NCT05931718","phase":"","title":"Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia","status":"RECRUITING","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2019-06-01","conditions":"Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, Chronic Idiopathic Neutropenia","enrollment":200},{"nctId":"NCT06581055","phase":"","title":"A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2024-11-30","conditions":"Myelodysplastic Syndromes (MDS)","enrollment":""},{"nctId":"NCT05005182","phase":"PHASE2","title":"Luspatercept With or Without Hydroxyurea for the Treatment of Myelodysplastic/Myeloproliferative Neoplasms With Ring Sideroblasts and Thrombocytosis or Unclassifiable With Ring Sideroblasts","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2023-02-20","conditions":"Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified, Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified","enrollment":3},{"nctId":"NCT01749514","phase":"PHASE2","title":"Study of Luspatercept for the Treatment of Anemia in Patients With Myelodysplastic Syndrome (MDS) (MK-6143-001)","status":"COMPLETED","sponsor":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","startDate":"2013-01-21","conditions":"Anemia","enrollment":116},{"nctId":"NCT02268383","phase":"PHASE2","title":"Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003)","status":"COMPLETED","sponsor":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","startDate":"2014-10-09","conditions":"Myelodysplastic Syndromes","enrollment":75},{"nctId":"NCT01749540","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of Luspatercept (ACE-536) in Participants With Beta-thalassemia (A536-04/MK-6143-002)","status":"COMPLETED","sponsor":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","startDate":"2013-02-28","conditions":"B-Thalassemia","enrollment":64},{"nctId":"NCT02268409","phase":"PHASE2","title":"Extension Study to Evaluate the Safety and Efficacy of Luspatercept in Participants With β-Thalassemia Previously Enrolled in A536-04 (A536-06/MK-6143-004)","status":"COMPLETED","sponsor":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","startDate":"2014-10-20","conditions":"β-Thalassemia","enrollment":51},{"nctId":"NCT04973280","phase":"","title":"Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs)","status":"COMPLETED","sponsor":"Celgene","startDate":"2021-07-26","conditions":"Myelodysplastic Syndromes, Beta-thalassemia","enrollment":187},{"nctId":"NCT06424639","phase":"PHASE4","title":"Luspatercept Plus CsA vs CsA for the Treatment of Newly Diagnosed Non-Transfusion-Dependent NSAA","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-05","conditions":"Aplastic Anemia","enrollment":58},{"nctId":"NCT05925504","phase":"PHASE2","title":"The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2023-07-01","conditions":"Lower Risk MDS Per IPSS-R","enrollment":36},{"nctId":"NCT06254781","phase":"NA","title":"Luspatercept in Metastatic AGCT of the Ovary","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2022-05-30","conditions":"Adult Granulosa Cell Tumor of the Ovary","enrollment":1},{"nctId":"NCT05384691","phase":"PHASE2","title":"Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions","status":"RECRUITING","sponsor":"University of Leipzig","startDate":"2022-09-27","conditions":"Myelodysplastic Syndromes, Anemia","enrollment":213},{"nctId":"NCT06164821","phase":"NA","title":"Clinical Observation of Luspatercept in Treatment of Chinese Adult β-thalassaemia Patients With TD β-thalassemia","status":"UNKNOWN","sponsor":"Hematology department of the 920th hospital","startDate":"2024-01-01","conditions":"Effect of Drug","enrollment":10},{"nctId":"NCT03342404","phase":"PHASE2","title":"A Study to Determine the Efficacy and Safety of Luspatercept in Adults With Non Transfusion Dependent Beta (β)-Thalassemia","status":"COMPLETED","sponsor":"Celgene","startDate":"2018-02-05","conditions":"Thalassemia","enrollment":145},{"nctId":"NCT04477850","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in Chinese and Japanese Participants With Ring Sideroblasts Who Require Red Blood Cell Transfusions","status":"UNKNOWN","sponsor":"Celgene","startDate":"2020-11-30","conditions":"Myelodysplastic Syndromes","enrollment":30},{"nctId":"NCT03194542","phase":"PHASE2","title":"A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence","status":"COMPLETED","sponsor":"Celgene","startDate":"2017-11-15","conditions":"Primary Myelofibrosis, Anemia","enrollment":95},{"nctId":"NCT06006949","phase":"PHASE4","title":"Roxadustat Combined With Luspatercept Versus Luspatercept Monotherapy in the Treatment of Refractory MDS-RS","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2023-08","conditions":"Myelodysplastic Syndromes","enrollment":62},{"nctId":"NCT02604433","phase":"PHASE3","title":"An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia","status":"COMPLETED","sponsor":"Celgene","startDate":"2016-05-02","conditions":"Erythrocyte Transfusion, Beta-Thalassemia","enrollment":336},{"nctId":"NCT05462548","phase":"PHASE4","title":"The Safety and Efficiency of Luspatercept in Chinese Adults With Transfusion Dependent β-thalassemia: a Real-world Study","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2022-07","conditions":"Thalassemia Major, Transfusion-dependent Anemia","enrollment":20},{"nctId":"NCT02631070","phase":"PHASE3","title":"A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Celgene","startDate":"2016-02-09","conditions":"Myelodysplastic Syndromes","enrollment":229},{"nctId":"NCT01432717","phase":"PHASE1","title":"Study of ACE-536 in Healthy Postmenopausal Women","status":"COMPLETED","sponsor":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","startDate":"2011-09","conditions":"Anemia","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Luspatercept","BMS-986346"],"phase":"phase_3","status":"active","brandName":"ACE-536","genericName":"ACE-536","companyName":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","companyId":"acceleron-pharma-inc-a-wholly-owned-subsidiary-of-merck-co-inc-rahway-nj-usa","modality":"Biologic","firstApprovalDate":"","aiSummary":"ACE-536 is an activin receptor ligand trap that inhibits activin signaling to promote erythropoiesis and increase hemoglobin levels. Used for Beta-thalassemia, Myelodysplastic syndromes (MDS).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}